

Press release

Reponex is the first Danish biotech company to be listed on the Copenhagen stock exchange in 6 years

On Tuesday, the Reponex stock will have its first trading day on Nasdaq Copenhagen, breaking a six-year drought in biotech listings on the main stock exchange in Copenhagen. In comparison, Sweden had five biotech listings in 2022 alone.

Copenhagen, March 27th, 2023 -- Reponex Pharmaceuticals A/S achieves an important milestone in the company's continued development as it has its first trading day on the main stock exchange in Copenhagen through the issuance of new shares in the publicly traded company Pharma Equity Group A/S. There has not been a Danish biotech listing since 2017, while Sweden had five biotech listings last year. In total, there were 40 company listings in Sweden in 2022 compared to three in Denmark.

"We are proud that Reponex, through Pharma Equity Group, is offered on the Main Market in Copenhagen. Reponex is a Danish biopharmaceutical company with a pipeline based on innovative thinking from Danish clinicians, and our clinical development is done in close collaboration with public research institutions and university hospitals in Denmark. Therefore, it is also natural that Reponex is listed in Denmark on Nasdaq Copenhagen," says Thomas Kaas Selsø, the expected CEO of Pharma Equity Group A/S and adds: "Furthermore, Denmark is a recognized country abroad for developing biotech and therefore a good starting point for the company's further development."

Reponex has six promising drug candidates in clinical development and testing in four areas, each characterized by a significant treatment need where Reponex is expected to offer better and/or cheaper treatments:

- Prevention of **colon and rectal cancer** and prevention of **metastases**
- Prevention and treatment of **bacterial peritonitis**
- Relief of symptoms of the inflammatory disorders **Crohn's disease** and **pouchitis**
- Treatment of **chronic wounds** and **infected chronic wounds**

"Reponex's repositioning strategy and model make it possible to meet patients' treatment needs faster than conventional drug development, while significantly reducing the total development costs and risks associated with drug development. With the listing, we have the opportunity to attract the investors needed to realize the significant potential in our business model and in getting our drug candidates all the way to the patients, where they can make a difference," says Thomas Kaas Selsø.

Reponex takes the drug candidates up to and including clinical phase 2, where a data basis has been obtained that confirms the drug's clinical relevance. The strategy is then to enter into licensing agreements with larger drug companies that can take the drugs further in the process towards final regulatory approval for marketing and distribution.

Reponex Pharmaceuticals is owned by Pharma Equity Group A/S (Nasdaq: **PEG A**; formerly BLVIS A), which invests in innovative life science companies.

###

Background information about the drug candidates: (<https://pharmaequitygroup.com/reponex/>)

Candidates	Disease area	Clinical phase	Patient population	Annual global market	Patent expiry
RNX-011	Prevention and treatment of bacterial peritonitis	II	Approximately 1.2 million new cases per year in the EU, USA, and Japan	Estimated: USD 1.5-2 billion	2035/2040
RNX-021 RNX-022	Treatment of chronic wounds	II	Approximately 16 million patients in the EU, USA, and Japan	USD 19 billion (2019)	2035
RNX-023	Treatment of infected chronic wounds	II	Approximately 2.5 million patients in the EU, USA, and Japan	Expected USD 25 billion (2025)	2035
RNX-041	Relief of symptoms of the inflammatory disorders Crohn's disease and pouchitis	II	Approximately 2 million patients in the EU and USA with Crohn's disease. Chronic pouchitis affects up to 10% of patients with proctocolectomy as a result of ulcerative colitis	USD 3.6 billion (2016) Expected: USD 4.7 billion (2025)	2035
RNX-051	Prevention of colon and rectal cancer and prevention of metastases	II	Approximately 1.5 million new cases per year in the western world	USD 9.4 billion (2020)	2039

About Pharma Equity Group A/S

Pharma Equity Group (PEG) is a publicly listed company on Nasdaq Copenhagen, focused on investing in innovative life science companies in or before clinical phase 2, developing technologies and therapies that have the potential to improve people's health and quality of life.

About Reponex Pharmaceuticals A/S

Reponex Pharmaceuticals is a Danish clinical-stage biopharmaceutical company developing drugs based on already established active pharmaceutical ingredients. This is done either by finding new indications, new ways of administering them, or by combining them with other active ingredients and/or drugs. The clinical development is done in close collaboration with public research institutions and university hospitals. The company is based in Hørsholm and has access to a range of international scientific capacities.

For further information:

Thomas Kaas Selsø, future expected CEO, Pharma Equity Group A/S, tel. +40 22 21 14.